An Open-Label, Multicenter, Non-Randomized Phase 2 Study Of Pf-06863135 Monotherapy In Participants With Multiple Myeloma Who Are Refractory To At Least One Proteasome Inhibitor, One Immunomodulatory Drug And One Anti-Cd38 Antibody Read more
A Phase Ib Study Of SAR650984 (Anti-CD38 Mab) In Combination With Carfilzomib For The Treatment Of Relapsed Or Refractory Multiple Myeloma Read more
A Phase 3 Randomized Study Comparing Teclistamab In Combination With Daratumumab SC (Tecdara) Versus Daratumumab SC, Pomalidomide And Dexamethasone (Dpd) Or Daratumumab SC, Bortezomib, And Dexamethasone (Dvd) In Participants With Relapsed Or Refractory Multiple Myeloma Read more
Treatment Patterns And Adverse Event Management In Patients Treated With Selinexor In Combination With Other Approved Agents For Relapsed/Refractory Multiple Myeloma: Real-World Evidence Based On Electronic Medical Record Data Read more
A Phase 3, Multicenter, Randomized, Open Label Study To Compare The Efficacy And Safety Of Bb2121 Versus Standard Triplet Regimens In Subjects With Relapsed And Refractory Multiple Myeloma Read more
A Phase 1, Open-Label, Multicenter Study To Evaluate The Safety Of Bb2121 In Subjects With High Risk, Actively Diagnosed Multiple Myeloma (Karmma-4) Read more
A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Assess The Safety, Tolerability, Pharmacokinetics And Efficacy Of CC-220 As Monotherapy And In Combination With Other Treatments In Subjects With Multiple Myeloma Read more
Phase I, Open Label Dose-Escalation Study To Evaluate The Safety, Expansion, Persistence And Clinical Activity Of UCARTCS1A (Allogeneic Engineered T-Cells Expressing Anti-CS1 Chimeric Antigen Receptor), Administered In Patients With Relapsed/Refractory Multiple Myeloma Read more
